Concludes a week-long series of expert discussions with a plenary overview of NanoHarmony’s efforts to support OECD test guideline development, stakeholder collaboration, and long-term regulatory impact for nanosafety.

Discusses the potential of non-animal models to transform safety assessment and therapeutic development, with insights from pandemic-driven advances in regulatory science.

This presentation focuses on the basic principles of matrix and biomarker selection in human biomonitoring, guiding participants from the identification of exposure biomarkers to their application in population studies. 

This presentation focuses on exhaled breath condensate (EBC) as a biological matrix for chromium biomonitoring, explaining its production, potential applications, and the procedures for sample collection. It outlines the method developed by the Health & Safety Laboratory in the UK for chromium speciation in EBC, supported by findings from a feasibility study. 

This presentation focuses on the molecular pathways involved in the development of asbestos-related diseases, emphasising the roles of oxidative stress, DNA repair, and xenobiotic metabolism. It explores how both germline mutations and single-nucleotide polymorphisms (SNPs) within these pathways influence individual susceptibility. By understanding these mechanisms, researchers can identify clinically relevant biomarkers that support early diagnosis and risk assessment.

Focuses on exploring the role of gene-environment interactions in disease development, using asbestosis as a case study to illustrate the combined impact of genetic and environmental factors. Highlights findings from a nested case-control study that incorporated cumulative asbestos exposure, smoking data, and PCR-based genotyping, with logistic regression used to assess risk. Emphasises the importance of investigating how genetic factors interact with lifestyle and occupational exposures to shape disease outcomes.